{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:28:02Z","timestamp":1789421282759,"version":"build-2803163510"},"reference-count":73,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,9]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The antiapoptotic protein BCL2 is a promising potential target in the treatment of CTCL. Combination inhibition of BCL2 and HDACs leads to efficient killing of CTCL cells due to the synergistic activation of apoptosis.<\/jats:p>","DOI":"10.1182\/blood-2017-06-792150","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:40:22Z","timestamp":1506991222000},"page":"2073-2083","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients"],"prefix":"10.1182","volume":"130","author":[{"given":"Benoit M.","family":"Cyrenne","sequence":"first","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Weed","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacie R.","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima N.","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[{"name":"Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-9343","authenticated-orcid":false,"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111904314850400_B1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111904314850400_B2","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"issue":"31","key":"2019111904314850400_B3","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111904314850400_B4","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2019111904314850400_B5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and azacitidine synergize in their epigenetic modulatory effects to induce apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111904314850400_B6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"2019111904314850400_B7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"2019111904314850400_B8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111904314850400_B9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2019111904314850400_B10","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-14-3322","article-title":"The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL)","volume":"21","author":"Litvinov","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111904314850400_B11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2019111904314850400_B12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jid.2016.10.037","article-title":"FISH panel for leukemic CTCL","volume":"137","author":"Weed","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"Pt 2","key":"2019111904314850400_B13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","article-title":"STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells","volume":"392","author":"Bhattacharya","year":"2005","journal-title":"Biochem J"},{"issue":"2","key":"2019111904314850400_B14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"issue":"9","key":"2019111904314850400_B15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00277-006-0127-z","article-title":"Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas","volume":"85","author":"Jung","year":"2006","journal-title":"Ann Hematol"},{"issue":"23","key":"2019111904314850400_B16","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2019111904314850400_B17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401415","article-title":"Inhibition of constitutively activated Stat3 correlates with altered Bcl-2\/Bax expression and induction of apoptosis in mycosis fungoides tumor cells","volume":"13","author":"Nielsen","year":"1999","journal-title":"Leukemia"},{"issue":"29","key":"2019111904314850400_B18","doi-asserted-by":"crossref","first-page":"45730","DOI":"10.18632\/oncotarget.10160","article-title":"STAT5 induces miR-21 expression in cutaneous T cell lymphoma","volume":"7","author":"Lindahl","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"2019111904314850400_B19","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood.V98.9.2778","article-title":"Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells","volume":"98","author":"Qin","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111904314850400_B20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.arcmed.2011.01.006","article-title":"Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells","volume":"42","author":"Dong","year":"2011","journal-title":"Arch Med Res"},{"issue":"2","key":"2019111904314850400_B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2019111904314850400_B22","volume-title":"Cell Health Cytoskeleton","author":"Grant","year":"2010"},{"issue":"6","key":"2019111904314850400_B23","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2005.07.002","article-title":"Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy","volume":"122","author":"Pattingre","year":"2005","journal-title":"Cell"},{"key":"2019111904314850400_B24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"17","key":"2019111904314850400_B25","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1182\/blood-2008-08-176024","article-title":"Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism","volume":"113","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111904314850400_B26","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Xargay-Torrent","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11-12","key":"2019111904314850400_B27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.18632\/genesandcancer.42","article-title":"The Bcl-2 inhibitor obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells","volume":"5","author":"Berghauser Pont","year":"2014","journal-title":"Genes Cancer"},{"issue":"13","key":"2019111904314850400_B28","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","article-title":"Romidepsin for cutaneous T-cell lymphoma","volume":"18","author":"Prince","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111904314850400_B29","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111904314850400_B30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","article-title":"Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin","volume":"7","author":"Newbold","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2019111904314850400_B31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol Clin"},{"issue":"10","key":"2019111904314850400_B32","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1038\/bcj.2015.83","article-title":"Romidepsin targets multiple survival signaling pathways in malignant T cells","volume":"5","author":"Valdez","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"2019111904314850400_B33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111904314850400_B34","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"11","key":"2019111904314850400_B35","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J"},{"issue":"21","key":"2019111904314850400_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3635.3635","article-title":"Activity of ABT-199 and acquired resistance in follicular lymphoma cells","volume":"124","author":"Bodo","year":"2014","journal-title":"Blood"},{"issue":"3 Pt 1","key":"2019111904314850400_B37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF02631086","article-title":"Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides","volume":"28A","author":"Kaltoft","year":"1992","journal-title":"In Vitro Cell Dev Biol"},{"issue":"1","key":"2019111904314850400_B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/1523-1747.ep12514693","article-title":"A clonal CD4-positive T-cell line established from the blood of a patient with S\u00e9zary syndrome","volume":"96","author":"Abrams","year":"1991","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2019111904314850400_B39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ijc.2910490218","article-title":"Establishment of an IL-2 independent, human T-cell line possessing only the p70 IL-2 receptor","volume":"49","author":"Starkebaum","year":"1991","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111904314850400_B40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V55.3.409.bloodjournal553409","article-title":"Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas","volume":"55","author":"Gazdar","year":"1980","journal-title":"Blood"},{"issue":"301","key":"2019111904314850400_B41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/01621459.1963.10500845","article-title":"Hierarchical grouping to optimize an objective function","volume":"58","author":"Ward","year":"1963","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2019111904314850400_B42","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"6","key":"2019111904314850400_B43","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111904314850400_B44","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaad.2015.12.018","article-title":"Cutaneous T-cell lymphoma (CTCL): current practices in blood assessment and the utility of T-cell receptor (TCR)-V\u03b2 chain restriction","volume":"74","author":"Gibson","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"25","key":"2019111904314850400_B45","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2019111904314850400_B46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2019111904314850400_B47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1039\/c3mb25410k","article-title":"Small-molecular modulators of cancer-associated epigenetic mechanisms","volume":"9","author":"Itoh","year":"2013","journal-title":"Mol Biosyst"},{"issue":"16","key":"2019111904314850400_B48","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1182\/blood-2012-04-423061","article-title":"Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts","volume":"120","author":"Lee","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111904314850400_B49","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J Exp Med"},{"issue":"16","key":"2019111904314850400_B50","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1158\/0008-5472.CAN-04-1253","article-title":"Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in S\u00e9zary syndrome identified by gene expression analysis","volume":"64","author":"van Doorn","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"2019111904314850400_B51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1365-2133.2010.09973.x","article-title":"Novel approach to gene expression profiling in S\u00e9zary syndrome","volume":"163","author":"Pomerantz","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"2019111904314850400_B52","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111904314850400_B53","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2019111904314850400_B54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111904314850400_B55","doi-asserted-by":"crossref","unstructured":"Seymour JF , MaS, BranderDM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230-240.","DOI":"10.1016\/S1470-2045(17)30012-8"},{"issue":"21","key":"2019111904314850400_B56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.304.304","article-title":"The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study","volume":"120","author":"Davids","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2019111904314850400_B57","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111904314850400_B58","article-title":"Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)","volume":"122","author":"Davids","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111904314850400_B59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2040620716655350","article-title":"The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia","volume":"7","author":"Itchaki","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2019111904314850400_B60","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2019111904314850400_B61","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/leu.2013.377","article-title":"BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines","volume":"28","author":"Anderson","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111904314850400_B62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"308","key":"2019111904314850400_B63","doi-asserted-by":"crossref","first-page":"308ra158","DOI":"10.1126\/scitranslmed.aaa9122","article-title":"TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL","volume":"7","author":"Kirsch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"2019111904314850400_B64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.canlet.2011.12.021","article-title":"BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions","volume":"332","author":"Del Gaizo Moore","year":"2013","journal-title":"Cancer Lett"},{"issue":"suppl 15","key":"2019111904314850400_B65","article-title":"BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia","volume":"75","author":"Hogdal","year":"2015","journal-title":"Cancer Res"},{"issue":"22","key":"2019111904314850400_B66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.292.292","article-title":"A functional characterization of BCL2-family members identifies BH3 mimetics as potential therapeutics in T-cell lymphomas","volume":"128","author":"Koch","year":"2016","journal-title":"Blood"},{"key":"2019111904314850400_B67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13048-016-0234-y","article-title":"Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells","volume":"9","author":"Abed","year":"2016","journal-title":"J Ovarian Res"},{"issue":"11","key":"2019111904314850400_B68","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"issue":"14","key":"2019111904314850400_B69","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2019111904314850400_B70","doi-asserted-by":"crossref","first-page":"34785","DOI":"10.18632\/oncotarget.9185","article-title":"Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"7","author":"Zhao","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2019111904314850400_B71","doi-asserted-by":"crossref","first-page":"e20987","DOI":"10.1371\/journal.pone.0020987","article-title":"Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells","volume":"6","author":"Petruccelli","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"2019111904314850400_B72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1593\/neo.81358","article-title":"Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment","volume":"11","author":"Yang","year":"2009","journal-title":"Neoplasia"},{"issue":"20","key":"2019111904314850400_B73","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/19\/2073\/1403292\/blood792150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/19\/2073\/1403292\/blood792150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T16:12:39Z","timestamp":1603037559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/19\/2073\/36684\/Synergy-of-BCL2-and-histone-deacetylase-inhibition"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,9]]},"references-count":73,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2017,11,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-792150","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,9]]}}}